This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: 26/10/2209    most recent 01.ATV.0000235605.51400.9dv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Crandall, D. L. Articles by Alessi, M.-C. Search for Related Content PubMed PubMed Citation Articles by Crandall, D. L. Articles by Alessi, M.-C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB GLUCOSE Related Collections Related Article

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:2209.)
© 2006 American Heart Association, Inc.

Vascular Biology

Modulation of Adipose Tissue Development by Pharmacological Inhibition of PAI-1

David L. Crandall; Elaine M. Quinet; Soulaf El Ayachi; Amy L. Hreha; Courtney E. Leik; Dawn A. Savio; Irene Juhan-Vague; Marie-Christine Alessi

From Cardiovascular and Metabolic Disease Research (D.L.C., E.M.Q., A.L.H., C.E.L., D.A.S.), Wyeth Research, Philadelphia, Pa; Laboratoire d’Hematologie UMR Inserm 626 (S.E.A., I.J.-V., M.-C.A.), Faculte de Medecine, Marseille, France.

Correspondence to David L. Crandall, Wyeth Research, N2265A, PO Box 42528, Philadelphia, PA 19101. E-mail crandad{at}wyeth.com

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Objective— The effect of a novel small molecule plasminogen activator inhibitor (PAI-1) inhibitor on adipose tissue physiology was investigated.

Methods and Results— In human preadipocyte cultures, PAI-039 inhibited both basal and glucose-stimulated increases in active PAI-1 antigen, yet had no effect on PAI-1 mRNA, suggesting a direct inactivation of PAI-1. Differentiation of human preadipocytes to adipocytes was associated with leptin synthesis, which was significantly reduced in the presence of PAI-039, together with an atypical adipocyte morphology characterized by a reduction in the size and number of lipid containing vesicles. In a model of diet-induced obesity, pair-fed C57 Bl/6 mice administered PAI-039 in a high-fat diet exhibited a dose-dependent reduction in body weight, epididymal adipose tissue weight, adipocyte volume, and circulating plasma active PAI-1. Plasma glucose, triglycerides, and leptin were also significantly reduced in drug-treated mice, and concentrations of PAI-039 associated with these physiological effects were near the in vitro IC₅₀ for the inhibition of PAI-1.

Conclusions— Our results indicate that a small molecule inactivator of PAI-1 can neutralize glucose-stimulated increases in PAI-1in human preadipocyte cultures, reduce adipocyte differentiation, and prevent the development of diet-induced obesity. These data suggest the pharmacological inhibition of PAI-1 could be beneficial in diseases associated with expansion of adipose tissue mass.

Pharmacological inhibition of PAI-1 was achieved in vitro and in vivo, resulting in effects on adipose tissue differentiation. PAI-1 inhibition may be beneficial in those diseases associated with increased adipose tissue mass, including diabetes and obesity.

Key Words: adipocyte • diabetes • obesity • PAI-1

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Type 2 diabetes accounts for >90% of diabetes globally and continues to increase at epidemic proportions.¹ Cardiovascular morbidity is a major burden in patients with type 2 diabetes, and their risk of death from cardiovascular disease is increased significantly over nondiabetic subjects.² Aggressive treatment of both diabetes and cardiovascular disease in this population through a combination of diet, exercise, and pharmacological therapy has recently been reported to result in a 20% reduction in cardiovascular events,³ whereas treatment of hyperglycemia alone produces less benefit.⁴ Taken together, a significant number of diabetics continue to exhibit vascular disease that is refractory to current therapy.

See page 2183

Plasminogen activator inhibitor-1 (PAI-1) is the principal inhibitor of both tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA),⁵ and is physiologically involved in both thrombosis and atherosclerosis.⁶ PAI-1 is found in the circulation of healthy individuals at low concentrations, and although it has a potential regulatory role in tumorigenesis, inflammation, and thrombosis,⁷ PAI-1 is both elevated in the plasma of type 2 diabetic patients and is an important predictor of the onset of the disease.⁸ The discovery that PAI-1 is synthesized by adipose tissue suggested that it represents a possible causal link between obesity and the increased atherothrombosis observed in diabetics. This hypothesis is further supported by additional studies establishing that plasma PAI-1 is elevated with obesity, is reduced with weight loss,^9–11 and correlates with the amount of visceral adipose tissue.¹² Although PAI-1 is elevated with obesity and type 2 diabetes, a causal role of PAI-1 has not been established in this disease caused in part by the absence of an agent that specifically normalizes elevated plasma PAI-1.

Our laboratory has recently identified a small molecule inhibitor of PAI-1 using a pharmacology-based approach of drug screening and medicinal chemical synthesis.¹³ The goal of the present research was to determine its effect on PAI-1 inactivation in human adipose tissue cultures and investigate the impact of pharmacological inhibition of PAI-1 on adipose tissue differentiation both in cell culture and in a murine model of diet-induced obesity. Ultimately, these data may be used to determine the role of adipose tissue PAI-1 neutralization on adipose tissue growth, development, and metabolism.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Preadipocyte Cell Culture
Human preadipocytes (#SP-F; Zen-Bio Inc, Research Triangle Park, NC) were grown to confluence using preadipocyte medium containing 10% fetal bovine serum (#PM-1; Zen-Bio Inc). The primary cultures were from females, ages 18 to 43, and body mass index ranging from 22 to 30, with 6 to 12 separate cultures used for each experiment. Preadipocytes at passage 2 to 3 were plated at 5000 cells/well in a 96-well plate and incubated at 37°C with 5% CO₂ for 24 hours. The media was then changed to 1% fetal bovine serum for 24 hours before addition of the drug. To determine the effect of PAI-039 on preadipocyte viability, cells were treated with PAI-039 at various concentrations, and cell number was determined 24, 48, and 72 hours later. For determination of the effect of PAI-039 on PAI-1, preadipocytes were treated with 24 mmol/L glucose at various concentrations of PAI-039 for 6 hours. Each treatment was performed in quadruplicate on the plate. Supernatant was collected for PAI-1 analysis (Imubind kit, #821; American Diagnostica, Greenwich, Conn) and cell number was determined using a fluorescent probe (CyQuant Assay, C-7026; Molecular Probes, Eugene, Ore).

Adipocyte Cell Culture
Preadipocytes were plated at 50 000 cells/well in a 12-well plate and incubated for 72 hours at 37°C with 5% CO₂ in preadipocyte medium, followed by addition of differentiation medium (DM-2/10; Zen-Bio) for 3 days. On day 4, the differentiation medium was replaced with adipocyte medium (#AM-1; Zen-Bio) containing in triplicate either 0.5% DMSO (controls) or an equal volume of various concentrations of PAI-039 in 0.5% DMSO. During the differentiation period, aliquots of conditioned medium were removed for determination of leptin concentration (R&D Systems, Minneapolis, Minn). Adipocyte morphology during differentiation was documented using a Zeiss Axiovert 25 microscope (Gottingen, Germany) interfaced to a QImaging digital camera (QImaging, Burnaby, Canada) processed through Image-Pro® Plus Version 4.5 software (Media Cybernetics, Inc, Silver Spring, Md). For determination of the effect of serpin-serine protease complexes on differentiation, a stable PAI-1 (C-PAI; Molecular Innovations, Southfield, Mich) was incubated with an equimolar concentration of tPA and added to the medium, which was then sequentially assayed for leptin.

Real-Time Quantitative Polymerase Chain Reaction
Please see http://atvb.ahajournals.org for details.

In Vivo Studies
PAI-039 was formulated into a high-fat diet containing 42% of calories from fat (Harlan-Teklad TD88137, Madison, Wis) at concentrations of 1 and 5 mg of compound per gram of chow. Control mice (Taconic; Germantown, NY) received only the high-fat diet. Male mice (n=6/group; C57Bl/6; Taconic, Germantown, NY) at 8 weeks of age were divided into groups of equal body weight. Pair-feeding was initiated by monitoring food intake within each treatment group, then matching food intake on a daily basis to the minimal amount of chow consumed by any treatment group the previous day. Body weights were monitored weekly. At the end of 4 weeks, animals were fasted overnight, and the next morning anesthetized with isoflurane, blood was withdrawn into a syringe containing sodium citrate, the contents were centrifuged, and plasma was collected and stored at –80°C. Epididymal adipose tissue and liver was dissected, rinsed with saline, blotted dry, and weighed. For determination of adipocyte cell size, each paired depot was incubated in Krebs-Ringer bicarbonate buffer containing 2 mg/mL of collagenase,¹⁴ and cells were isolated according to a previously published method.¹⁵ The diameter of 100 cells from each depot was determined and cell volume was calculated.¹⁵ One epididymal adipose tissue depot per animal was snap-frozen for isolation of mRNA. Plasma PAI-1 levels were determined for both active PAI-1 and total antigen using kits from Molecular Innovations (Southfield, Mich). Plasma glucose, cholesterol, and triglycerides were determined with a Hitachi 911 (Roche Diagnostics, Indianapolis, Ind) clinical autoanalyzer. Plasma leptin (R&D Systems, Minneapolis, Minn) and insulin (Linco, Inc, St. Charles, Mo) were determined using commercially available kits. Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) was calculated according to the method of Matthews et al.¹⁶ Pharmacokinetic analyses were performed to determine the volume of distribution and metabolism of PAI-039. Plasma drug concentrations for both the volume of distribution and in vivo efficacy studies were determined by liquid chromatography-tandem mass spectrometry.¹³

Statistical Analysis
Statistical analysis was performed using an ANOVA for multiple groups. Comparison between preadipocytes and adipocytes used a 1-sided t test. Group means±SEM were considered significantly different at P<0.05.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Effect of PAI-039 on PAI-1 Secretion by Preadipocytes: Basal and Glucose-Stimulated Conditions
Preliminary experiments were performed to determine whether PAI-039 had any cytotoxic or mitogenic effects. PAI-039 was added at different concentrations to preadipocyte cultures (up to 50 µmol/L), and cell number was determined over a 3-day period. Cells were plated at 5000 cells per well on day 1, and by day 3 cell number was equivalent between treatments with and without PAI-039, resulting in an average of 8159±104 cells, indicating that concentrations of PAI-039 up to 50 µmol/L had no effect on preadipocyte viability and was not mitogenic. PAI-1 was measured using a commercially available antibody capture technique that detects active and latent PAI-1 as antigen. Preliminary experiments indicated that active PAI-1 inhibited by PAI-039 resulted in a reduction in PAI-1 antigen. These data confirm that the inactivation of PAI-1 in the presence of inhibitor results in a reduction in active PAI-1 antigen without affecting mass.

We next determined the effect of PAI-039 on basal levels of PAI-1 antigen in preadipocyte conditioned medium. Over a 6-hour period, preadipocytes released 25.4±3.1 ng/mL per 1000 cells of PAI-1 antigen under control conditions, whereas this value was reduced to 18.1±1.3 ng/mL per 1000 cells in drug-treated cultures (20 µmol/L of PAI-039; P<0.05), indicating that PAI-039 could reduce the basal levels of PAI-1 after release by preadipocytes. In the presence of 24 mmol/L glucose, a 2.5-fold increase in PAI-1 (P<0.05) was observed compared with control values, which was decreased in a concentration-dependent pattern by the addition of PAI-039, reaching statistical significance at 20 µmol/L of PAI-039 (P<0.05) (Figure 1). Cell number was determined in the same wells, and again, was not affected by PAI-039, indicating that the reduction in PAI-1 antigen was caused by a direct action of the compound, and not variability in cell number as a result of the culture conditions.

View larger version (18K): [in this window] [in a new window]   Figure 1. Effect of PAI-039 on glucose-stimulated active PAI-1 antigen levels in conditioned medium of human preadipocytes (*P<0.05 vs glucose alone). Black bars, cell number; white bars, PAI-1 antigen.

To confirm that compensatory effects on PAI-1 mRNA do not account for the PAI-039–induced reduction in PAI-1 antigen, gene expression studies were performed. An initial control time course analysis of the effect of 24 mmol/L glucose on the expression of PAI-1 by human preadipocytes indicated a 2-fold increase after 2 hours of stimulation, which returned to basal levels at 6 and 24 hours. In separate experiments, both glucose and PAI-039 were added to preadipocytes, and gene expression determined. When compared with the effect of 24 mmol/L glucose treatment alone, no change in PAI-1 gene expression was observed in cells treated with PAI-039 (5 to 50 µmol/L). When comparing values between glucose-stimulated cells to those treated with 20 µmol/L PAI-039, PAI-1 mRNA expression normalized to cyclophilin mRNA was similar between treatments, again indicating that the treatment of the cells with the compound did not affect PAI-1 gene expression (data not shown).

Effect of PAI-039 on Adipocyte Differentiation
Because differentiation uses a serum-free defined medium differing in composition from the preadipocyte medium, an initial PAI-039 dose-response was performed in differentiating adipocytes. As shown in Figure 2, a dose-dependent reduction in PAI-1 antigen was associated with PAI-039 treatment. In the serum-free differentiation medium, the compound also exhibited increased potency, as concentrations from 1 to 5 µmol/L reduced PAI-1 antigen at each time point assayed between 4 and 8 days (P<0.01). The effect of PAI-039 on adipocyte differentiation was next determined by assaying leptin in the conditioned medium, and through microscopic imaging of the differentiating adipocytes. Addition of 5 µmol/L PAI-039 was associated with suppression of the elevated leptin observed in control cells that readily differentiated into adipocytes (Figure 2). In addition, a 90% decrease in leptin mRNA was observed concurrently in the presence of 5 µmol/L PAI-039 (Figure 2). Peroxisome proliferator-activated receptor (PPAR) mRNA was also reduced (supplemental Figure I, available online at http://atvb.ahajournals.org). Image analysis indicated that PAI-039 treatment resulted in the maintenance of many cells as preadipocytes, as well as a reduction in both the size and number of lipid vesicles within differentiating adipocytes (Figure 3). Finally, addition of inactive protein complexes of PAI-1 and tPA dose-dependently (500 nM and 50 nM) inhibited leptin production (supplemental Figure II).

View larger version (16K): [in this window] [in a new window]   Figure 2. A, PAI-1 antigen secretion during adipocyte differentiation without (; solid line) or with 1(), 2.5 (), 5 (•) µM PAI-039. Supernatants were harvested every 48 hours. Values are mean±SEM of 6 different wells. B, Leptin secretion during adipocyte differentiation without (; solid line) or with (•) 5 µmol/L PAI-039. Supernatants were harvested every 48 hours. Values are mean±SEM of 5 wells. Insert corresponds to leptin mRNA from cells differentiated during 8 days in absence (–) or presence (+) of 5 µmol/L PAI-039.

View larger version (72K): [in this window] [in a new window]   Figure 3. Morphology of cultured human adipocytes treated with 5 µmol/L PAI-039. Adipocytes were imaged at day 8 after the analysis of leptin concentration in the conditioned medium. A=Control; B=PAI-039–treated.

In Vivo Studies
Using a pair-feeding regimen, the highest dose of PAI-039 resulted in a significant reduction in body weight gain and final body weight compared with control mice (Figure 4; Table 1). The mean body weight of each group was equal at the beginning of the study, but significant changes in gain were observed throughout the 4 weeks of study, with those animals receiving the highest concentration of the drug exhibiting the lowest body weights. Although liver weight was unaffected by the drug treatments, epididymal adipose tissue weight and adipocyte volume was reduced (Table 1). Statistically significant reductions in adipose tissue weight and cell volume were observed at the highest dose, and the percentage decrease compared with controls was approximately equivalent for each value. The contribution of the preadipocyte population was not directly determined in these analyses, because only lipid-containing mature adipocytes were counted. Circulating levels of active PAI-1 was also reduced with drug treatment, with the greatest impact seen in the 5-mg PAI-039 group (P<0.05). PAI-039 treatment was associated with significant reductions in plasma triglycerides, glucose and leptin (Table 2). In addition, a significant (P<0.01) decrease in adipose tissue leptin mRNA was observed in the 5 mg PAI-039 group (supplemental Figure III). Plasma cholesterol and insulin were unchanged. HOMA-IR (mmol/L*mU/L) was 21.9±3.0 for the control, 21.9±6.2 for the low-dose and 13.4±2.5 for the high-dose PAI-039–treated group (P<0.05 versus control).

View larger version (11K): [in this window] [in a new window]   Figure 4. Growth curves of mice fed either a high-fat diet (control) or diet containing PAI-039. **P<0.01 compared with control values with n=6 mice/group.

View this table: [in this window] [in a new window]   TABLE 1. Effect of High-Fat Diet With or Without PAI-039 on Body Weight, Epididymal Adipose Tissue Morphology, and Plasma PAI-1

View this table: [in this window] [in a new window]   TABLE 2. Effect of High-Fat Diet With or Without PAI-039 on Plasma Metabolic Parameters

Pharmacokinetic studies indicated that PAI-039 had a low volume of distribution, poor tissue penetration, high protein binding, and was not extensively metabolized. PAI-039 was excreted predominantly unchanged in the bile and feces, suggesting that after inactivation of PAI-1, it would facilitate clearance of the protein. Plasma concentrations of PAI-039 increased dose-proportionally, with 1.6±0.26 µg/mL for the low-dose group, and 8.3±1.3 µg/mL for the high-dose group (3.6±0.6 and 18.8±3.0 µmol/L, respectively).

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
There is an established relationship between human obesity and plasma PAI-1, with increased body mass index directly correlated to circulating levels of the serpin. Investigations using human adipose tissue explants and primary cell culture have shown that human adipose tissue is a rich source of PAI-1 protein^17,18 that directly contributes to increased plasma concentrations in obesity,^9,10,11 and is synthesized by both preadipocytes and adipocytes. The health outcomes impact associated with increased plasma PAI-1 is significant, with data from the Insulin Resistance Atherosclerosis Study (IRAS) study supporting a role for elevated plasma PAI-1 in the development of type 2 diabetes⁸ independent of insulin resistance. PAI-1 deficiency also retards the development of diabetic nephropathy in streptozotocin-induced diabetes.¹⁹ In addition, PAI-1 synthesis is stimulated by a variety of other factors, including cytokines, lipids, and growth factors, and its production by and action on the vasculature can directly impact the etiology of atherosclerosis.²⁰ Because PAI-039 is an orally active direct inhibitor of PAI-1 that exhibits efficacy in models of acute thrombosis and accelerated atherosclerosis,^13,21,22 we decided to evaluate its effects on adipose tissue development and diet-induced obesity.

PAI-039 dose-dependently reduced both basal and glucose-stimulated active PAI-1 antigen in human preadipocytes without affecting PAI-1 gene expression, indicating that the inhibition of PAI-1 was through direct interaction with the target protein. PAI-039 treatment also retarded the differentiation of preadipocytes to adipocytes when assessed by leptin synthesis and cellular morphology. Because inhibition of adipocyte differentiation by small molecule PPAR antagonists has been reported,²³ the effect of PAI-039 on PPARs was determined as part of the development of this compound. In a cofactor recruitment assay, PAI-039 had no effect on PPAR or PPAR, and exhibited partial agonist characteristics for PPAR, but at concentrations several fold greater than those associated with inhibition of adipogenesis. We next tested PAI-039 in vivo both to further explore the various hypotheses on the role of PAI-1 in obesity and to extend our own cell culture findings. We initially observed an inverse correlation between plasma active PAI-1 and plasma concentrations of PAI-039, which importantly were below the no toxic effect level of the drug.¹³ Oral administration of PAI-039 in a high-fat diet also resulted in a dose-dependent reduction in body weight and epididymal adipose tissue mass. PAI-039 treatment was also associated with an improved metabolic profile, evidenced by a reduction in plasma glucose, triglyceride, leptin, and HOMA-IR, all of which could have been contributed to by the significantly smaller adipocytes in the drug-treated mice.²⁴ Our in vivo observations are therefore consistent with recently published findings in which adipose tissue weight was reduced in PAI-1 null mice on a high-fat diet.²⁵ Lijnen et al have also shown that administration of PAI-039 for 4 weeks improved insulin sensitivity in wild-type mice on a standard chow diet.²⁶

The mechanistic basis for the effect of PAI-039 on prevention of diet-induced obesity could be multifaceted, including regulation of cell migration, angiogenesis and lipid metabolism. Active migration of human preadipocytes is stimulated by latent PAI-1,²⁷ and inactivation of PAI-1 by PAI-039 would produce similar results, suggesting that increased potential for migration could reduce adipose tissue differentiation. This hypothesis is supported by reduced leptin after PAI-1 inhibition in developing adipocytes in culture, and histological studies indicating that preadipocytes require attachment and cessation of migration before differentiation into mature adipocytes.²⁸ A second potential mechanism may be through inhibition of angiogenesis, as leptin has been shown to stimulate neovascularization in adipose tissue,²⁹ and its reduction after PAI-039 treatment would negatively impact adipose tissue vascularity. Finally, PAI-1 may affect adipose tissue growth by competing for clearance receptors that also transport lipid into the cell, because a reduction in leptin was also observed in human cultures in the presence of inactive PAI-1/tPA complexes. Low-density lipoprotein receptor-related protein has recently been described as an important alternative pathway for selective uptake of lipid into fat cells,³⁰ and the inactive PAI-1/tPA complex has a high affinity for this receptor.³¹ The plasminogen activator-PAI-1 complex also has a high affinity for the very-low-density lipoprotein receptor,³² and mice lacking this receptor are protected from obesity.³³ These results suggest a novel, autocrine role for PAI-1 in regulation of adipocyte lipid metabolism through competition with ligands for lipoprotein receptors. This is the first observation to our knowledge of regulation of adipocyte metabolism by a serpin.

The elevation of plasma PAI-1 observed in human obesity together with the absence of a definitive function for PAI-1 in adipose tissue has prompted the use of a variety of transgenic animal models to better understand these interrelationships. Disparate findings have resulted from these investigations, however, describing a role of PAI-1 in either preventing^25,34 or promoting^35,36 obesity. Differences in mouse strain³⁵ and the high tissue concentrations of PAI-1 produced by the PAI-1 transgene³⁶ may have contributed to these differences. Clinically, the development of human obesity is associated with both increased adipose tissue mass and elevated plasma PAI-1, and for both end points we observed an increase in the control mice, and a reduction after treatment with PAI-039. Our observations are further supported by a recent study by Ma et al²⁵ in which PAI-1 null mice were protected from the development of obesity and insulin resistance when fed a high-fat diet. Whether PAI-1 directly affects key regulatory processes of metabolism is not well understood, but an increased resting metabolic rate has been reported for PAI-1 null mice.²⁵ Another intriguing observation is that vitronectin binding to the _vß₃ integrin facilitates insulin signaling in 3T3 cells, and this response is blocked by PAI-1 through competition for this binding site.³⁷ Finally, a very recent study has shown a clear effect of the proinflammatory mediators IL-6 and oncostatin M on the stimulation of PAI-1 by human adipose tissue.³⁸ Inhibition of this elevation by PAI-039 would therefore reduce the consequences of an inflammatory milieu of the adipocyte, which could ultimately contribute to prevention of insulin resistance.³⁹

Because other classes of drugs have been tested for effects on PAI-1 in culture systems, the magnitude of the PAI-039 response can be comparatively estimated. Glucose-stimulated increases in PAI-1 are seen in arterial endothelial cells⁴⁰ and vascular smooth muscle cells,⁴¹ and the Sp1 binding site in the PAI-1 promoter has been characterized as critical for this response.⁴² Specific drugs known to be beneficial to diabetic patients have also been used to attenuate PAI-1 mRNA and protein in cultured cells, and some comparison to PAI-039 is warranted. Troglitazone reduces PAI-1 antigen in cultured human adipocytes predominantly through regulation at the transcriptional level,⁴³ simvastatin reduces PAI-1 gene expression in human vascular smooth muscle and endothelial cells,⁴⁴ and niacin attenuates the expression of PAI-1 mRNA and the rate of PAI-1 protein synthesis in human liver cells.⁴⁵ The concentration of each drug required for an inhibitory effect was similar to PAI-039, yet the studies differ mechanistically, because PAI-039 directly inactivated PAI-1 without affecting gene expression. These data would suggest that combinations of PAI-039 with molecules from the statin or glitazone class could further reduce PAI-1.

The search for novel therapies for the treatment of cardiovascular and metabolic disease continues as the incidence of obesity and type 2 diabetes increases,⁴⁶ while remaining largely refractory to current therapies. We have identified a small molecule inhibitor of PAI-1 that directly impacts adipose tissue differentiation in vitro and in vivo. Although additional studies are required to determine the potentially multiple mechanisms resulting in these effects, PAI-039 represents an important tool in furthering the understanding of PAI-1 as either a risk factor or risk marker in this population.

	Acknowledgments

 
We appreciate the constructive comments and assistance of Drs James Tobin and David Erbe, and the technical expertise of Viera Kasparcova, Wyeth Research.

Disclosures

None.

	Footnotes

 
Original received April 28, 2006; final version accepted June 19, 2006.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Zimmet P. Addressing the insulin resistance syndrome. Trends Cardiovasc Med. 2002; 12: 354–362.[CrossRef][Medline] [Order article via Infotrieve]
2. Luscher T, Creager M, Beckman J, Consentino F. Diabetes and vascular disease. Circulation. 2003; 108: 1655–1661.[Free Full Text]
3. Gaede P, Vedel P, Larsen N, Jensen G, Parving H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348: 383–393.[Abstract/Free Full Text]
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998; 352: 837–853.[CrossRef][Medline] [Order article via Infotrieve]
5. Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in cardiovascular disease. J Investigative Med. 1998; 46: 370–376.[Medline] [Order article via Infotrieve]
6. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 1991; 34: 457–462.[CrossRef][Medline] [Order article via Infotrieve]
7. Binder BR, Christ G, Gruber F, Grubic, Hufnagl P, Krebs M, Mihaly J, Prager GW. Plasminogen activator inhibitor-1: physiological and pathophysiological roles. NIPS. 2002; 17: 56–61.[Abstract/Free Full Text]
8. Festa A, D’Agostino R, Tracy R, Haffner S. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. Diabetes. 2002; 51: 1131–1137.[Abstract/Free Full Text]
9. Kockx M, Leenen R, Seidell J, Princen HMG, Kooistra T. Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss. Thromb Haemost. 1999; 82: 1490–1496.[Medline] [Order article via Infotrieve]
10. Mavri A, Stegnar M, Krebs M, Sentocnik J, Geiger M, Binder B. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arterioscler Thromb Vasc Biol. 1999; 19: 1582–1587.[Abstract/Free Full Text]
11. Eriksson P, Reynisdottir S, Lonnqvist F, Stemme V, Hamsten, Arner P. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia. 1998; 41: 65–71.[CrossRef][Medline] [Order article via Infotrieve]
12. Janand-Delenne B, Chagnaud C, Raccah D, Alessi MC, Juhan-Vague I, Vague P. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obesity Related Metab Dis. 1998; 22: 312–317.
13. Elokdah H, Abou-Gharbia M, Hennan JK, McFarlane G, Mugford CP, Krishnamurthy G, Crandall DL. Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: Design, synthesis, and preclinical characterization. J Med Chem. 2004; 47: 3491–3494.[CrossRef][Medline] [Order article via Infotrieve]
14. Rodbell M. Metabolism of isolated fat cells. J Biol Chem. 1964; 239: 375–380.[Free Full Text]
15. Crandall DL, Herzlinger HE, Saunders BD, Armellino DC, Kral JG. Distribution of angiotensin II receptors in rat and human adipocytes. J Lipid Res. 1994; 35: 1378–1385.[Abstract]
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and ß-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412–419.[CrossRef][Medline] [Order article via Infotrieve]
17. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. 1997; 46: 860–867.[Abstract]
18. Crandall DL, Quinet EM, Morgan GA, Busler DE, Mchendry-Rinde B, Kral JG. Synthesis and secretion of plasminogen activator inhibitor-1 by human preadipocytes. J Clin Endocrinol Metab. 1999; 84: 3222–3227.[Abstract/Free Full Text]
19. Nicholas SB, Aguiniga E, Ren Y, Kim J, Wong J, Govindarajan N, Noda M, Wang W, Kawano Y, Collins A, Hseuh WA. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kid Int. 2005; 67: 1297–1307.[CrossRef][Medline] [Order article via Infotrieve]
20. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost. 2005; 1: 1879–1883.
21. Hennan JK, Elokdah H, Leal M, Ji A, Friedrichs GS, Morgan GA, Swillo RE, Antrilli TM, Hreha A, Crandall DL. Evaluation of PAI-039, a novel PAI-1 inhibitor, in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther. 2005; 314: 710–716.[Abstract/Free Full Text]
22. Weisberg AD Albornoz F, Griffin JP, Crandall DL, Elokdah H, Fogo AB, Vaughan DE, Brown NJ. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioslcer Thromb Vasc Biol. 2005; 25: 1–7.[Free Full Text]
23. Camp HS, Chaudhry A, Leff T. A novel potent antagonist of peroxisome proliferator-activated receptor blocks adipocyte differentiation but does not revert the phenotype of terminally differentiated adipocytes. Endocrinology. 2001; 142: 3207–3213.[Abstract/Free Full Text]
24. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T. Troglitazone increases the number of small adipocytes without change of white adipose tissue mass in obese zucker rats. J Clin Invest. 1998; 101: 1354–1361.[Medline] [Order article via Infotrieve]
25. Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift L, McGuinness O, Wasserman D, Vaughan DE, Fogo AB. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor-1. Diabetes. 2004; 53: 336–346.[Abstract/Free Full Text]
26. Lijnen HR, Alessi MC, Van Hoef B, Collen D, Juhan-Vague I. On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. J Thrombosis Haemostasis. 2005; 3: 1174–1179.
27. Crandall DL, Busler D, McHendry-Rinde B, Groeling T, Kral JG. Autocrine regulation of human preadipocyte migration by plasminogen activator inhibitor-1. J Clin Endocrinol Metab. 2000; 85: 2609–2614.[Abstract/Free Full Text]
28. Crandall DL, Hausman G, Kral JG. A review of the microcirculation of adipose tissue: anatomic, metabolic and angiogenic perspectives. Microcirculation. 1997; 4: 211–232.[Medline] [Order article via Infotrieve]
29. Sierra-Honigmann MC, Nath A, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa W, Madge L, Schechner J, Schwabb M, Polverini P, Flores-Riveros J. Biologic action of leptin as an angiogenic factor. Science. 1998; 281: 1683–1686.[Abstract/Free Full Text]
30. Vassiliou G, McPherson R. A novel efflux-recapture process underlies the mechanism of high-density lipoprotein cholesteryl ester-selective uptake mediated by the low-density lipoprotein receptor-related protein. Arterioscler Thromb Vasc Biol. 2004; 24: 1669–1675.[Abstract/Free Full Text]
31. Kasza A, Petersen H, Heegaard C, Oka K, Christensen A, Dubin A, Chan L, Andreasen P. Specificity of serine proteinase/serpin complex binding to very-low-density lipoprotein receptor and ₂-macroglobulin receptor/low-density-lipoprotein-receptor-related-protein. Eur J Biochem. 1997; 248: 270–281.[Medline] [Order article via Infotrieve]
32. Argraves KM, Battey FD, MacCalman CD, McCrae KR, Gafvels M, Kozarsky KF, Chappell DA, Strauss JF, Strickland DK. The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plaminogen activator inhibitor type I complexes. J Biol Chem. 1995; 270: 26550–26557.[Abstract/Free Full Text]
33. Goudriaan JR, Tacken PJ, Dahlmans V, Gijbels M, van Dijk K, Havekes LM, Jong MC. Protection from obesity in mice lacking the VLDL receptor. Arterioscler Thromb Vasc Biol. 2001; 21: 1488–1493.[Abstract/Free Full Text]
34. Schafer K, Fujisawa K, Konstantinides S, Loskutoff D. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J. 2001; 15: 1840–1842.[Free Full Text]
35. Morange PE, Lijnen HR, Alessi MC, Kopp F, Collen D, Juhan-Vague I. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol. 2000; 20: 1150–1154.[Abstract/Free Full Text]
36. Lijnen HR, Maquoi E, Morange P, Voros G, Van Hoef B, Kopp F, Collen D, Juhan-Vague I, Alessi M. Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol. 2003; 23: 78–84.[Abstract/Free Full Text]
37. Lopez-Alemany R, Redondo JM, Nagamine Y, Munoz-Canoves P. Plasminogen activator inhibitor-1 inhibits insulin signaling by competing with the _Vß₃ integrin for vitronectin binding. Eur J Biochem. 2003; 270: 814–821.[Medline] [Order article via Infotrieve]
38. Rega G, Kaun C, Weiss TW, Demyanets S, Kastl SP, Steiner S, Seidinger D, Kopp CW, Frey M, Roehle R, Mauer G, Huber K, Wojta J. Inflammatory cytokines interleukin-6 and oncostatin M induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation. 2005; 111: 1938–1945.[Abstract/Free Full Text]
39. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003; 112: 1821–1830.[CrossRef][Medline] [Order article via Infotrieve]
40. Nordt T, Klassen K, Schneider D, Sobel B. Augumentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb. 1993; 13: 1822–1828.[Abstract/Free Full Text]
41. Pandolfi A, Iacoviello L, Capani F, Vitacolonna E, Donati M, Consoli A. Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture. Diabetologia. 1996; 39: 1425–1431.[CrossRef][Medline] [Order article via Infotrieve]
42. Chen Y, Su M, Walia R, Hao Q, Covington J, Vaughan DE. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem. 1998; 273: 8225–8231.[Abstract/Free Full Text]
43. Gottschling-Zeller H, Rohrig K, Hauner H. Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes. Diabetologia. 2000; 43: 377–383.[CrossRef][Medline] [Order article via Infotrieve]
44. Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol. 2000; 20: 556–562.[Abstract/Free Full Text]
45. Brown S, Sobel B, Fujii S. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. Circulation. 1995; 92: 767–772.[Abstract/Free Full Text]
46. Kereiakes D, Willerson J. Metabolic syndrome epidemic. Circulation. 2003; 108: 1552–1553.[Free Full Text]

Related Article:

A Role for Plasminogen Activator Inhibitor-1 in Obesity: From Pie to PAI?

Marcelo L.G. Correia and William G. Haynes
Arterioscler. Thromb. Vasc. Biol. 2006 26: 2183-2185. [Full Text] [PDF]

This article has been cited by other articles:

				H. R. Lijnen Angiogenesis and obesity Cardiovasc Res, May 1, 2008; 78(2): 286 - 293. [Abstract] [Full Text] [PDF]

				L. Jensen, B. Sloth, I. Krog-Mikkelsen, A. Flint, A. Raben, T. Tholstrup, N. Brunner, and A. Astrup A low-glycemic-index diet reduces plasma plasminogen activator inhibitor-1 activity, but not tissue inhibitor of proteinases-1 or plasminogen activator inhibitor-1 protein, in overweight women Am. J. Clinical Nutrition, January 1, 2008; 87(1): 97 - 105. [Abstract] [Full Text] [PDF]

				P. F. Bodary Links Between Adipose Tissue and Thrombosis in the Mouse Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2284 - 2291. [Abstract] [Full Text] [PDF]

				J. Harslund, O. L. Nielsen, N. Brunner, and H. Offenberg Gender-dependent physiological implications of combined PAI-1 and TIMP-1 gene deficiency characterized in a mouse model Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1630 - R1639. [Abstract] [Full Text] [PDF]

				E. Ingelsson, M. J. Pencina, G. H. Tofler, E. J. Benjamin, K. J. Lanier, P. F. Jacques, C. S. Fox, J. B. Meigs, D. Levy, M. G. Larson, et al. Multimarker Approach to Evaluate the Incidence of the Metabolic Syndrome and Longitudinal Changes in Metabolic Risk Factors: The Framingham Offspring Study Circulation, August 28, 2007; 116(9): 984 - 992. [Abstract] [Full Text] [PDF]

				N. V. Gorlatova, J. M. Cale, H. Elokdah, D. Li, K. Fan, M. Warnock, D. L. Crandall, and D. A. Lawrence Mechanism of Inactivation of Plasminogen Activator Inhibitor-1 by a Small Molecule Inhibitor J. Biol. Chem., March 23, 2007; 282(12): 9288 - 9296. [Abstract] [Full Text] [PDF]

				M. L.G. Correia and W. G. Haynes A Role for Plasminogen Activator Inhibitor-1 in Obesity: From Pie to PAI? Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2183 - 2185. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Data Supplement All Versions of this Article: 26/10/2209    most recent 01.ATV.0000235605.51400.9dv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Crandall, D. L. Articles by Alessi, M.-C. Search for Related Content PubMed PubMed Citation Articles by Crandall, D. L. Articles by Alessi, M.-C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB GLUCOSE Related Collections Related Article